Bridgefront Capital’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
ACA
Bridgefront Capital's CYTK Position: Q2 2026 in Review
Bridgefront Capital opened a new position in Cytokinetics (CYTK) in Q2 2026: 4,731 shares worth $403K. The stake represents 0.11% of the portfolio and ranks #303 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in CYTK as recently as Q4 2025.
Bridgefront Capital first reported a position in CYTK in Q1 2024 and has held it in 5 quarters since. The position peaked at $603K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Bridgefront Capital held 4,731 shares of Cytokinetics worth $403K as of Q2 2026.
- Cytokinetics was a new Bridgefront Capital position in Q2 2026.
- Cytokinetics made up 0.11% of Bridgefront Capital's portfolio in Q2 2026, its #303 holding.
- Bridgefront Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 5 quarters since.
- Bridgefront Capital's Cytokinetics position peaked at $603K in Q4 2025.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.